Contenders in the Vaccine Race

These stocks could benefit from the race to roll out antibody therapy for COVID-19

Vikram Barhat 14 October, 2020 | 12:23AM

Tablets

All eyes were on U.S. President Donald Trump and First Lady Melania Trump as they became the latest in a growing list of prominent figures who have tested positive for the dreaded coronavirus. These high-profile cases put the spotlight back on the race for coronavirus vaccine, particularly the antibody therapy that the U.S. president was administered at the Walter Reed military hospital.

Antibody drugs, derived from naturally occurring COVID-19 antibodies, work by galvanizing an immune defense by generating antibodies that help combat the coronavirus. Rather than wait for human system to produce antibodies and fight off pathogens, the therapy’s goal is to boost the immune system’s defenses to mount a robust response to infection. This could be particularly effective for patients with weak immune system which makes them susceptible to life-threatening cases of COVID-19.

Investors looking to take a shot at the coronavirus vaccine play, potentially a US$40 billion market, may want to keep tabs on these drugmakers that boast both a well-established and highly profitable portfolio of drug,s and a robust pipeline. Remember, though, their their COVID-19 treatments are still being tested and have not yet been cleared for widespread use by regulators.

Regeneron Pharmaceuticals Inc
  Ticker REGN
  Current yield: -
  Forward P/E: 16.29
  Price US$595.93
  Fair value: US$500
  Value 20% premium
  Moat Narrow
  Moat Trend Positive
  Star rating **
Data as of Oct 09, 2020


Biotech firm Regeneron Pharmaceuticals (REGN) develops treatments for eye disease, cardiovascular disease, cancer, and inflammation. The firm is also developing various antibody drugs in collaboration and independently.

The drugmaker has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to successfully emerge as a profitable commercial operation. Regeneron recently announced it had submitted a request for emergency authorization to the Food and Drug Administration for its experimental antibody treatment, the therapy that was prescribed to President Donald Trump as part of his COVID-19 treatment plan.

Data from a trial of the coronavirus antibody cocktail, REGN-COV2, in nonhospitalized patients “reflects a strong profile and solid potential to benefit patients with high viral loads who have failed to form an immune response to the virus,” says a Morningstar equity report, noting that “based on the data, we’ve increased our assumed probability of approval for REGN-COV2 to 100% from 60%.”

Regeneron expects to have supply to treat 300,000 COVID-19 patients later this year as part of the US$450 million U.S. government contract, says Morningstar sector strategist, Karen Andersen, who recently upped the stock’s fair value from US$473 to US$500.

 

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

Want More Actionable Content In Your Inbox?

Sign Up For Our Newsletter Here

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar Rating
AstraZeneca PLC ADR53.07 USD2.06
Eli Lilly and Co141.70 USD-0.48
GlaxoSmithKline PLC ADR35.22 USD-0.20
Regeneron Pharmaceuticals Inc585.74 USD1.02

About Author

Vikram Barhat

Vikram Barhat  Vikram Barhat is a Toronto-based financial writer specializing in investing, stock markets, personal finance and other areas of the financial services industry. He also writes for CNBC, BBC, The Globe and Mail, and Toronto Star.

© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies